Pooling data from 4 studies [21, 25, 32, 35] with 1507 participants showed that there was a linear dose-response relationship between circulating AdipoQ levels and HCC risk (Pnon-linearity = 0.233). The gene discussed is ADIPOQ; the disease is hepatocellular carcinoma.